Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-11-14
DOI
10.1002/cam4.2705
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
- (2019) Margaret A. Tempero et al. JOURNAL OF CLINICAL ONCOLOGY
- European cancer mortality predictions for the year 2018 with focus on colorectal cancer
- (2018) M Malvezzi et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
- (2018) Junko Tahara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study
- (2018) S. Karim et al. CLINICAL ONCOLOGY
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?
- (2018) Monika K. Krzyzanowska et al. Journal of Oncology Practice
- Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
- (2018) Sunnie Kim et al. ADVANCES IN THERAPY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
- (2016) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Edward P. Balaban et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- PD-0018 * AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER
- (2014) S. Hollmann et al. ANNALS OF ONCOLOGY
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
- (2014) Kelvin Chan et al. PLoS One
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type I Error Rates, Coverage of Confidence Intervals, and Variance Estimation in Propensity-Score Matched Analyses
- (2009) Peter C Austin
- Generalizing the Results of Cancer Clinical Trials
- (2009) Ralph M. Meyer JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation